DGAP-News: Epigenomics AG: Epigenomics' methylated SHOX2 Biomarker shows promising results for Therapy Monitoring of Lung Cancer Patients
(firmenpresse) - DGAP-News: Epigenomics AG / Key word(s): Study
Epigenomics AG: Epigenomics' methylated SHOX2 Biomarker shows
promising results for Therapy Monitoring of Lung Cancer Patients
20.11.2013 / 15:15
---------------------------------------------------------------------
- Methylated SHOX2 allows rapid and sensitive determination of tumor
response and therapy monitoring in plasma of lung cancer patients
- Multi-centric study with larger patient population planned for
verification
- Further demonstrates commercial value of Epigenomics' DNA methylation
platform
Berlin, Germany and U.S.A., November 20, 2013 - Epigenomics AG (Frankfurt
Prime Standard: ECX, OTC: EPGNY), the German-American cancer molecular
diagnostics company, today announced the results from a clinical study
conducted by Dr. rer. nat. M. Fleischhacker and PD Dr. med. B. Schmidt from
the Department of Pulmonology of University Hospital (UKH) Halle/Saale
The study demonstrated methylated SHOX2 to be a sensitive and specific
biomarker for therapy monitoring and early detection of tumor response in
lung cancer patients. The blinded study was conducted between December 2012
and June 2013, whereby blood samples from a total of 32 advanced stage lung
cancer patients were taken prior to and during therapy every seven to ten
days for approximately three months. Re-staging after that period was
confirmed by a local tumor board based on clinical and imaging (CT scan)
results. Epigenomics' proprietary biomarker mSHOX2 was detected using a
modified Epi proLung(R) BL assay.
At re-staging, 14 out of the 32 patients with progressive disease showed no
change or an increase in the amount of methylated SHOX2. 13 patients with
treatment response showed a decrease of methylated SHOX2 under therapy. In
the majority of patients this response to therapy was seen at the time of
second blood draw. By the time of blood draw four, i.e. 4 weeks after start
of therapy, a decrease of methylated SHOX2 was observed in all patients.
Five patients, who had received a therapy before enrollment in the study,
were negative for methylated SHOX2 from the very beginning. The results of
this study were recently presented by Dr. M. Fleischhacker at the CNAPS
VIII meeting in Baltimore.
'The results reported in this study demonstrate further potential of our
proprietary SHOX2 DNA methylation biomarker. Cell-free mSHOX2 DNA isolated
from plasma and bronchial lavage has already proven to be a sensitive and
specific marker for the detection of lung cancer. It is exciting to see
that the biomarker additionally enables rapid and sensitive determination
of tumor response and therapy monitoring', said Dr. Uwe Staub, COO of
Epigenomics. 'As of today there is no sensitive and standardized biomarker
to indicate a patient's response to therapy or the need to change a therapy
due to tumor progression in lung cancer patients.'
An additional multi-centric study with a larger patient population is
planned to verify these exciting initial results.
- Ends -
Contact Epigenomics AG
Antje Zeise, Manager IR | PR
Epigenomics AG
Kleine Praesidentenstrasse 1
10178 Berlin
Tel +49 (0) 30 24345 386
ir(at)epigenomics.com
www.epigenomics.com
For US press inquiries:
Epigenomics, Inc.
9700 Great Seneca Highway Rockville
Maryland 20850
pr(at)epigenomics.com
About Epigenomics
Epigenomics (www.epigenomics.com) is a molecular diagnostics company
developing and commercializing a pipeline of proprietary products for
cancer. The Company's products enable doctors to diagnose cancer earlier
and more accurately, leading to improved outcomes for patients.
Epigenomics' lead product, Epi proColon(R), is a blood-based test for the
early detection of colorectal cancer, which is currently marketed in Europe
and is under regulatory review for the U.S.A. The Company's technology and
products have been validated through multiple partnerships with leading
global diagnostic companies and testing laboratories. Epigenomics is an
international company with operations in Europe and the U.S.A.
Epigenomics legal disclaimer
This communication expressly or implicitly contains certain forward-looking
statements concerning Epigenomics AG and its business. Such statements
involve certain known and unknown risks, uncertainties and other factors
which could cause the actual results, financial condition, performance or
achievements of Epigenomics AG to be materially different from any future
results, performance or achievements expressed or implied by such
forward-looking statements. Epigenomics AG is providing this communication
as of this date and does not undertake to update any forward-looking
statements contained herein as a result of new information, future events
or otherwise.
The information contained in this communication does not constitute nor
imply an offer to sell or transfer any product, and no product based on
this technology is currently available for sale by Epigenomics in the
United States or Canada. The analytical and clinical performance
characteristics of any Epigenomics product based on this technology which
may be sold at some future time in the U.S. have not been established.
End of Corporate News
---------------------------------------------------------------------
20.11.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Epigenomics AG
Kleine Präsidentenstraße 1
10178 Berlin
Germany
Phone: +49 30 24345-0
Fax: +49 30 24345-555
E-mail: ir(at)epigenomics.com
Internet: www.epigenomics.com
ISIN: DE000A1K0516
WKN: A1K051
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
240880 20.11.2013
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 20.11.2013 - 15:15 Uhr
Sprache: Deutsch
News-ID 318716
Anzahl Zeichen: 8128
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 342 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Epigenomics AG: Epigenomics' methylated SHOX2 Biomarker shows promising results for Therapy Monitoring of Lung Cancer Patients"
steht unter der journalistisch-redaktionellen Verantwortung von
Epigenomics AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
